Annual Meeting of the American Association for the Surgery of Trauma. Halifax, Nova Scotia (CAN), 1995/09/27.
High-dose Solu-Medrol (Upjohn, Kalamazoo, Mich) therapy has become standard care in the management of acute spinal cord injury (ASCI).
This study attempts to define the adverse effects that Solu-Medrol therapy has on these patients.
Retrospective review with historical control.
From May 1990 to April 1994, all patients with ASCI admitted within 8 hours of injury received high-dose Solu-Medrol per the National Acute Spinal Injury Study (NASCIS-2) protocol.
Their demographic and outcome parameters were compared with those of a group admitted from March 1986 to December 1993 with an associated ASCI who received no steroid therapy.
Steroid therapy was associated with a 2.6-fold increase in the incidence of pneumonia and an increase in ventilated and intensive care days.
However, it was associated with a decrease in duration of rehabilitation and had no significant impact on other outcome parameters, including mortality.
Although the NASCIS-2 protocol may promote early infectious complications, it has no adverse impact on long-term outcome in patients with ASCIs.
Mots-clés Pascal : Traumatisme, Moelle épinière, Traitement, Stéroïde, Chimiothérapie, Dose forte, Epidémiologie, Complication, Incidence, Unité soin intensif, Hospitalisation, Pronostic, Pneumonie, Homme, Système nerveux pathologie, Système nerveux central pathologie, Moelle épinière pathologie, Appareil respiratoire pathologie, Poumon pathologie
Mots-clés Pascal anglais : Trauma, Spinal cord, Treatment, Steroid, Chemotherapy, High dose, Epidemiology, Complication, Incidence, Intensive care unit, Hospitalization, Prognosis, Pneumonia, Human, Nervous system diseases, Central nervous system disease, Spinal cord disease, Respiratory disease, Lung disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0234184
Code Inist : 002B16B. Création : 11/06/1997.